In the last trading session, 1.1 million ITeos Therapeutics Inc (NASDAQ:ITOS) shares changed hands as the company’s beta touched 1.51. With the company’s per share price at $10.04 changed hands at -$0.13 or -1.28% during last session, the market valuation stood at $384.26M. ITOS’s last price was a discount, traded about -80.58% off its 52-week high of $18.13. The share price had its 52-week low at $4.80, which suggests the last value was 52.19% up since then. When we look at ITeos Therapeutics Inc’s average trading volume, we note the 10-day average is 2.64 million shares, with the 3-month average coming to 1.19 million.
Analysts gave the ITeos Therapeutics Inc (ITOS) stock a consensus recommendation rating of Buy, calculated at a mean rating of 2.67. If we narrow down to specifics, the data shows that 0 out of 1 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended ITOS as a Hold, 1 felt it is a Buy and 0 rated the stock as Underweight.
ITeos Therapeutics Inc (NASDAQ:ITOS) trade information
Instantly ITOS was in red as seen at the end of in last trading. With action 0.30%, the performance over the past five days has been green. The company’s shares are showing year-to-date upside of 30.73%, with the 5-day performance at 0.30% in the green. However, in the 30-day time frame, ITeos Therapeutics Inc (NASDAQ:ITOS) is 49.85% up. Looking at the short shares, we see there were 2.74 million shares sold at short interest cover period of 1.88 days.
The consensus price target for the stock as assigned by Wall Street analysts is 12, meaning bulls need an upside of 16.33% from its current market value. According to analyst projections, ITOS’s forecast low is 9 with 12 as the target high. To hit the forecast high, the stock’s price needs a -19.52% plunge from its current level, while the stock would need to tank 10.36% for it to hit the projected low.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -34.39%. The 2025 estimates are for ITeos Therapeutics Inc earnings to increase by 15.74%, but the outlook for the next 5-year period is at 3.89% per year.
ITOS Dividends
ITeos Therapeutics Inc is expected to release its next quarterly earnings report on 2025-Apr-27.
ITeos Therapeutics Inc (NASDAQ:ITOS)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 1.14% of ITeos Therapeutics Inc shares while 114.78% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 116.10%. There are 114.78% institutions holding the ITeos Therapeutics Inc stock share, with BLACKROCK INC. the top institutional holder. As of 2024-06-30, the company held 9.3983% of the shares, roughly 3.73 million ITOS shares worth $55.37 million.
RA CAPITAL MANAGEMENT, L.P. holds the second largest percentage of outstanding shares, with 8.8598% or 3.52 million shares worth $52.2 million as of 2024-06-30.
Among Mutual Funds, the top two as of Mar 31, 2025 were VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and iShares Trust-iShares Russell 2000 ETF . With 946.43 shares estimated at $9.5 million under it, the former controlled 2.47% of total outstanding shares. On the other hand, iShares Trust-iShares Russell 2000 ETF held about 1.75% of the shares, roughly 671.42 shares worth around $6.74 million.
